Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs

Nature Medicine

Volumn 10, Issue 10, 2004, Pages 1055-1063

  Forman, Mark S ^a   Trojanowski, John Q ^a   Lee, Virginia M Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PRION PROTEIN; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL NUCLEUS; CREUTZFELDT JAKOB DISEASE; CYTOSOL; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; EXTRACELLULAR SPACE; GENE MUTATION; GENETIC IDENTIFICATION; HUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PROCESSING; REVIEW; TAUOPATHY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYOTROPHIC LATERAL SCLEROSIS; CREUTZFELDT-JAKOB SYNDROME; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEWY BODIES; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PEPTIDES; PRIONS; PROTEIN FOLDING; SUPEROXIDE DISMUTASE; SYNUCLEINS;

EID: 7044238416     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1113     Document Type: Review

References (105)

1. Alzheimer, A. Über eine eigenartige Eskrankung der Nirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. 64, 146-148 (1907).
2. Lewy, F. in Handbuch der Neurologie, 3, 920-933. Springer Vertag, Berlin (1912).
3. Glenner, G.G. & Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (1984).
4. Lee, V.M.-Y., Balin, B.J., Otvos, L., Jr. & Trojanowski, J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251, 675-678 (1991).
5. Spillantini, M.G. et al. α-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
6. Prusiner, S.B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982).
7. World Health Organization. Active ageing: a policy framework. Second United Nations World Assembly on Aging, Madrid, Spain (World Health Organization, Geneva, 2002). www.who.int/hpr/ageing/ActiveAgingPolicyFrame.pdf
8. Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A. & Evans, D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60, 1119-1122 (2003).
9. Wancata, J., Musalek, M., Alexandrowicz, R. & Krautgartner, M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur. Psychiatry 18, 306-313 (2003).
10. Hartl, F.U. & Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295, 1852-1858 (2002).
11. Chartier-Harlin, M.C. et al. Early-onsef alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353, 844-846 (1991).
12. Rogaev, E.I. et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778 (1995).
13. Levy-Lahad, E. et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977 (1995).
14. Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760 (1995).
15. Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991).
16. De Strooper, B. & Annaert, W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci. 113, 1857-1870 (2000).
17. Haass, C. & De Strooper, B. The presenilins in Alzheimer's disease - proteolysis holds the key. Science 286, 916-919 (1999).
18. Price, D.L. & Sisodia, S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21, 479-505 (1998).
19. De Strooper, B. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 38, 9-12 (2003).
20. Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
21. Corder, E.H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993).
22. Bales, K.R. et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17, 263-264 (1997).
23. Poirier, J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 9, 94-101 (2003).
24. Puglielli, L., Tanzi, R.E. & Kovacs, D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6, 345-351 (2003).
25. Tanzi, R.E. & Bertram, L. New frontiers in Alzheimer's disease genetics. Neuron 32, 181-184 (2001).
26. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
27. Launer, L. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs 63, 731-739 (2003).
28. Götz, J. et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 9, 664-683 (2004).
29. Bonini, N.M. & Fortini, M.E. Human neurodegenerative disease modeling using Drosophila. Annu. Rev. Neurosci. 26, 627-656 (2003).
30. Götz, J., Chen, F., Van Dorpe, J. & Nitsch, R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 293, 1491-1495 (2001).
31. Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP Science 293, 1487-1491 (2001).
32. Oddo, S., Billings, L., Kesslak, J.P., Cribbs, D.H. & LaFerla, FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332 (2004).
33. Monsonego, A. & Weiner, H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302, 834-838 (2003).
34. Oddo, S., Billings, L., Kesslak, J.P., Cribbs, D.H. & LaFerla, F.M. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332 (2004).
35. Lee, V.M.-Y., Goedert, M. & Trojanowski, J.Q. Neurodegenerative tauopathies. Ann. Rev. Neurosci. 24, 1121-1159 (2001).
36. Hutton, M. et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998).
37. Poorkaj, P. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825 (1998).
38. Spillantini, M.G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 95, 7737-7741 (1998).
39. Billingsley, M.L. & Kincaid, R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 323, 577-591 (1997).
40. Yen, S.H., Hutton, M., DeTure, M., Ko, L.W. & Nacharaju, P. Fibrillogenesis of tau: insights from tau missense mutations in FTDP-17. Brain Pathol. 9, 695-705 (1999).
41. Wittmann, C.W. et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711-714 (2001).
42. Giasson, B.I. et al. Initiation and synergistic fibrillization of tau and α-synuclein. Science 300, 636-640 (2003).
43. Goedert, M. α-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501 (2001).
44. Polymeropoulos, M.H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
45. Kruger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108 (1998).
46. Singleton, A.B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).
47. Zarranz, J.J. et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173 (2004).
48. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306 (2000).
49. Ischiropoulos, H. Oxidative modifications of α-synuclein. Ann. N.Y. Acad. Sci. 991, 93-100 (2003).
50. Maries, E., Dass, B., Collier, T.J., Kordower, J.H. & Steece-Collier, K. The role of α-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4, 727-738 (2003).
51. Auluck, P.K. & Bonini, N.M. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8, 1185-1186 (2002).
52. Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M.-Y. & Bonini, N.M. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868 (2002).
53. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
54. Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452 (1998).
55. Giasson, B.I. & Lee, V.M.-Y. Are ubiquitination pathways central to Parkinson's disease? Cell 114, 1-8 (2003).
56. Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003).
57. Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004).
58. Zoghbi, H.Y. & Orr, H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
59. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. & Fischbeck, K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79 (1991).
60. Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558 (1997).
61. Lin, X., Cummings, C.J. & Zoghbi, H.Y. Expanding our understanding of polyglutamine diseases through mouse models. Neuron 24, 499-502 (1999).
62. Skinner, P.J. et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389, 971-974 (1997).
63. Ross, C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19, 1147-1150 (1997).
64. Bonini, N.M. Chaperoning brain degeneration. Proc. Natl. Acad. Sci. USA 99, 16407-16411 (2002).
65. Ross, C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35, 819-822 (2002).
66. Lipinski, M.M. & Yuan, J. Mechanisms of cell death in polyglutamine expansion diseases. Curr. Opin. Pharmacol. 4, 85-90 (2004).
67. Bence, N.F., Sampat, R.M. & Kopito, R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).
68. La Spada, A.R. & Taylor, J.P. Polyglutamines placed into context. Neuron 38, 681-684 (2003).
69. Lomen-Hoerth, C. et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 60, 1094-1097 (2003).
70. Bruijn, L.I., Miller, T.M. & Cleveland, D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723-749 (2004).
71. Hadano, S. et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 29, 166-173 (2001).
72. Yang, Y. et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 29, 160-165 (2001).
73. Puls, I. et al. Mutant dynactin in motor neuron disease. Nat. Genet. 33, 455-456 (2003).
74. Hafezparast, M. et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300, 808-812 (2003).
75. Rosen, D.R. et al. Mutations in Cu/Zn Superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62 (1993).
76. Julien, J.P. Amyotrophic lateral sclerosis, unfolding the toxicity of the misfolded. Cell 104, 581-591 (2001).
77. Bruijn, L.I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854 (1998).
78. Clement, A.M. et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302, 113-117 (2003).
79. Prusiner, S.B., Scott, M.R., DeArmond, S.J. & Cohen, F.E. Prion protein biology. Cell 93, 337-348 (1998).
80. Collinge, J. Variant Creutzfeldt-Jakob disease. Lancet 354, 317-323 (1999).
81. Collins, S.J., Lawson, V.A. & Masters, C.L. Transmissible spongiform encephalopathies. Lancet 363, 51-61 (2004).
82. Kocisko, D.A. et al. Cell-free formation of protease-resistant prion protein. Nature 370, 471-474 (1994).
83. Weissmann, C. & Flechsig, E. PrP knock-out and PrP transgenic mice in prion research. Br. Med. Bull. 66, 43-60 (2003).
84. Telling, G.C. et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83, 79-90 (1995).
85. Chesebro, B. BSE and prions: uncertainties about the agent. Science 279, 42-43 (1998).
86. Legname, G. et al. Synthetic mammalian prions. Science 305, 673-676 (2004).
87. Brown, P. Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 58, 1720-1725 (2002).
88. Uptain, S.M. & Lindquist, S. Prions as protein-based genetic elements. Annu. Rev. Microbiol. 56, 703-741 (2002).
89. King, C.Y. & Diaz-Avalos, R. Protein-only transmission of three yeast prion strains. Nature 428, 319-323 (2004).
90. Tanaka, M., Chien, P., Naber, N., Cooke, R. & Weissman, J.S. Conformational variations in an infectious protein determine prion strain differences. Nature 428, 323-328 (2004).
91. Knopman, D.S. et al. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62, 1087-1095 (2003).
92. Koistinaho, M. et al. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. USA 98, 14675-14680 (2001).
93. Caughey, B. & Lansbury, PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
94. Sisodia, S.S. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell 95, 1-4 (1998).
95. Klement, I.A. et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53 (1998).
96. Ma, J., Wollmann, R. & Lindquist, S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298, 1781-1785 (2002).
97. Stamer, K., Vogel, R., Thies, E., Mandelkow, E. & Mandelkow, E.M. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051-1063 (2002).
98. Walsh, D.M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
99. Conway, K.A., Harper, J.D. & Lansbury, P.T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320 (1998).
100. Taylor, J.P., Hardy, J. & Fischbeck, K.H. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
101. Selkoe, D.J. Folding proteins in fatal ways. Nature 426, 900-904 (2003).
102. Wolozin, B. & Behl, C. Mechanisms of neurodegenerative disorders: Part 1: protein aggregates. Arch. Neurol. 57, 793-796 (2000).
103. Liu, J. et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 43, 5-17 (2004).
104. Pasinelli, P. et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43, 19-30 (2004).
105. Forman, M.S. Genotype-phenotype correlations in FTDP-17: does form follow function? Exp. Neurol. 187, 229-234 (2004).